Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report
Coronavirus disease 2019 (COVID-19) is currently a major public health problem. The development of pulmonary fibrosis secondary to acute respiratory distress syndrome (ARDS) is one of the expected sequelae. In this case series, we describe five instances of the use of anakinra in late-phase COVID-19...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
SMC MEDIA SRL
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2c88b730844e40fd9fd30026631acb45 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:2c88b730844e40fd9fd30026631acb45 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:2c88b730844e40fd9fd30026631acb452021-11-09T11:21:27ZDelayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report2284-259410.12890/2021_002821https://doaj.org/article/2c88b730844e40fd9fd30026631acb452021-10-01T00:00:00Zhttps://www.ejcrim.com/index.php/EJCRIM/article/view/2821https://doaj.org/toc/2284-2594Coronavirus disease 2019 (COVID-19) is currently a major public health problem. The development of pulmonary fibrosis secondary to acute respiratory distress syndrome (ARDS) is one of the expected sequelae. In this case series, we describe five instances of the use of anakinra in late-phase COVID-19 pneumonia in hospitalized patients with pulmonary fibrosis and refractory respiratory failure fulfilling ARDS criteria. The study demonstrates that anakinra has promising efficacy and safety in late-phase COVID-19 infection in patients with ARDS and refractory hypoxaemia, and suggests its potential application as antifibrotic therapy in these patients.Daniel NanCristina Abraira-MerielSandra de la Roz-FernandezTamara Maestre-OrozcoJose Luis HernandezMarta Fernandez-AyalaSMC MEDIA SRLarticlepulmonary fibrosiscovid-19anakinraMedicineRENEuropean Journal of Case Reports in Internal Medicine (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
pulmonary fibrosis covid-19 anakinra Medicine R |
| spellingShingle |
pulmonary fibrosis covid-19 anakinra Medicine R Daniel Nan Cristina Abraira-Meriel Sandra de la Roz-Fernandez Tamara Maestre-Orozco Jose Luis Hernandez Marta Fernandez-Ayala Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report |
| description |
Coronavirus disease 2019 (COVID-19) is currently a major public health problem. The development of pulmonary fibrosis secondary to acute respiratory distress syndrome (ARDS) is one of the expected sequelae. In this case series, we describe five instances of the use of anakinra in late-phase COVID-19 pneumonia in hospitalized patients with pulmonary fibrosis and refractory respiratory failure fulfilling ARDS criteria. The study demonstrates that anakinra has promising efficacy and safety in late-phase COVID-19 infection in patients with ARDS and refractory hypoxaemia, and suggests its potential application as antifibrotic therapy in these patients. |
| format |
article |
| author |
Daniel Nan Cristina Abraira-Meriel Sandra de la Roz-Fernandez Tamara Maestre-Orozco Jose Luis Hernandez Marta Fernandez-Ayala |
| author_facet |
Daniel Nan Cristina Abraira-Meriel Sandra de la Roz-Fernandez Tamara Maestre-Orozco Jose Luis Hernandez Marta Fernandez-Ayala |
| author_sort |
Daniel Nan |
| title |
Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report |
| title_short |
Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report |
| title_full |
Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report |
| title_fullStr |
Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report |
| title_full_unstemmed |
Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report |
| title_sort |
delayed use of the recombinant human il-1 receptor antagonist anakinra in five covid-19 patients with pulmonary fibrosis and persistent hypoxaemia: a preliminary report |
| publisher |
SMC MEDIA SRL |
| publishDate |
2021 |
| url |
https://doaj.org/article/2c88b730844e40fd9fd30026631acb45 |
| work_keys_str_mv |
AT danielnan delayeduseoftherecombinanthumanil1receptorantagonistanakinrainfivecovid19patientswithpulmonaryfibrosisandpersistenthypoxaemiaapreliminaryreport AT cristinaabrairameriel delayeduseoftherecombinanthumanil1receptorantagonistanakinrainfivecovid19patientswithpulmonaryfibrosisandpersistenthypoxaemiaapreliminaryreport AT sandradelarozfernandez delayeduseoftherecombinanthumanil1receptorantagonistanakinrainfivecovid19patientswithpulmonaryfibrosisandpersistenthypoxaemiaapreliminaryreport AT tamaramaestreorozco delayeduseoftherecombinanthumanil1receptorantagonistanakinrainfivecovid19patientswithpulmonaryfibrosisandpersistenthypoxaemiaapreliminaryreport AT joseluishernandez delayeduseoftherecombinanthumanil1receptorantagonistanakinrainfivecovid19patientswithpulmonaryfibrosisandpersistenthypoxaemiaapreliminaryreport AT martafernandezayala delayeduseoftherecombinanthumanil1receptorantagonistanakinrainfivecovid19patientswithpulmonaryfibrosisandpersistenthypoxaemiaapreliminaryreport |
| _version_ |
1718441093749538816 |